CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product sales	$ 526,388	$ 597,514
License fee and other revenues	1,095	15,107
Research and development	163,007	129,185
Total revenues	690,490	741,806
Costs and Expenses:
Costs of goods sold	70,180	255,105
Research and development	17,341,528	14,525,864
Sales and marketing	226,100	215,856
General and administrative	4,650,303	691,584
Total costs and expenses	22,288,111	15,688,409
Operating loss	(21,597,621)	(14,946,603)
Changes in fair market value of warrant liabilities	(86,378,330)
Interest expense	(2,646,901)	(1,369,955)
Interest and other income, net	416,239	85,206
Loss on induced exchanges of debt	(13,005,329)
Insurance reimbursement	4,366,137
Foreign currency transaction gain, net	83,621	2,459
Loss before income tax benefit	(118,762,184)	(16,228,893)
Net loss	(118,762,184)	(16,228,893)
Less: Net loss attributable to noncontrolling interest	(17,636)	(31,045)
Net loss attributable to Immunomedics, Inc. stockholders	$ (118,744,548)	$ (16,197,848)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.97)	$ (0.17)
Weighted average shares used to calculate loss per common share (basic and diluted)	122,550,144	95,883,729
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (73,133)	$ 37,108
Unrealized gain (loss) on securities available for sale	32,133	(32,609)
Other comprehensive (loss) income, net of tax:	(41,000)	4,499
Comprehensive loss	(118,803,184)	(16,224,394)
Less comprehensive loss attributable to noncontrolling interest	(17,636)	(31,045)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (118,785,548)	$ (16,193,349)